Biogen Inc

2026. g. 13. aug. 20:06 UTC

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

2026. g. 12. aug. 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

2026. g. 11. aug. 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

2026. g. 10. aug. 19:36 UTC

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

2026. g. 7. aug. 23:16 UTC

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

2026. g. 6. aug. 23:11 UTC

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

2026. g. 5. aug. 19:26 UTC

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

2026. g. 4. aug. 20:02 UTC

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

2026. g. 3. aug. 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

2026. g. 31. jūl. 21:01 UTC

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

2026. g. 30. jūl. 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

2026. g. 29. jūl. 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

2026. g. 28. jūl. 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

2026. g. 24. jūl. 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

2026. g. 22. jūl. 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

2026. g. 21. jūl. 19:46 UTC

BIIB trading higher after Guggenheim raised price target to $280.

2026. g. 20. jūl. 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

2026. g. 17. jūl. 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

2026. g. 16. jūl. 19:02 UTC

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

2026. g. 15. jūl. 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

2026. g. 14. jūl. 23:41 UTC

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

2026. g. 13. jūl. 23:06 UTC

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

2026. g. 10. jūl. 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

2026. g. 9. jūl. 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

2026. g. 8. jūl. 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

2026. g. 7. jūl. 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

2026. g. 6. jūl. 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2026. g. 2. jūl. 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

2026. g. 1. jūl. 20:07 UTC

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.